Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 4, 2014, Pages 559-562

  Lammers, Philip E ^a   Shyr, Yu ^b   Li, Chung I ^b   Hutchison, Anne Smith ^c   Sandler, Alan ^d   Carbone, David Paul ^e   Johnson, David H ^f   Keedy, Vicki Leigh ^b   Horn, Leora ^b  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c South Carolina Oncology Associates   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bendamustine; Phase II; Refractory; Relapsed; Small cell lung cancer

Indexed keywords

BENDAMUSTINE; ALKYLATING AGENT; CHLORMETHINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BRONCHITIS; CANCER GROWTH; CANCER RECURRENCE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HIP FRACTURE; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NORTH AMERICAN; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SMALL CELL LUNG CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PROGNOSIS; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84922481992     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000079     Document Type: Article

References (12)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Tiseo M, Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2007; 2: 764-772.
3. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-667.
4. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447.
5. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-4384.
6. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116: 106-114.
7. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 204-210.
8. Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007; 55: 109-113.
9. Ebi N, Kubota K, Nishiwaki Y, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997; 27: 166-169.
10. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive smallcell lung cancer. J Clin Oncol 2001; 19: 1743-1749.
11. Bernard M, Brignone M, Adehossi A, et al. Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study. Lung Cancer 2011; 72: 114-118.
12. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95: 155-163.